Takeda Pharmaceutical's ACTOS Oral Antidiabetic Agent Proves in the PROactive Study to Reduce Risk of Heart Attack and Stroke in Type 2 Diabetics.Tokyo, Japan, Sept 13, 2005 - (JCNN JCNN Japan Corporate News Network ) - Landmark data from the PROactive Study, presented September 13 at the 41st meeting of the European Association for the Study of Diabetes (EASD EASD See: European Association of Securities Dealers ) demonstrated that Takeda Pharmaceutical's ACTOS(R) (pioglitazone HCl) significantly reduces the combined risk of heart attacks, strokes and death by 16% in high risk patients with type 2 diabetes type 2 diabetes n. See diabetes mellitus. . The PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events Study) showed that ACTOS (generic name: pioglitazone HCI (Human Computer Interaction) Refers to the design and implementation of computer systems that people interact with. It includes desktop systems as well as embedded systems in all kinds of devices. ), an oral antidiabetic agent, can reduce the risk of developing and dying of cardiovascular diseases including heart attack and strokes in type 2 diabetics. The PROactive study is a randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, placebo-controlled outcome study that determines the effects of ACTOS in type 2 diabetics who have a history of heart attack, coronary-artery bypass surgery and stroke. The study was co-conducted by Takeda Pharmaceutical and Eli Lilly in 19 European countries involving 5,238 patients. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion